| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now.
|
|
Today’s Big NewsApr 21, 2025 |
| By Kevin Dunleavy Revenues boomed for the top 20 companies in the biopharma industry in 2024, with only one company (Bayer) seeing a revenue decline last year. Six drugmakers saw their sales rise by double-digit percentages, led by Eli Lilly (32%) and Novo Nordisk (26%). |
|
|
|
By Gabrielle Masson,Darren Incorvaia The National Institutes of Health (NIH) is halting new grant and contract payments to several universities, a move the agency has been instructed not to disclose to the affected schools, according to several reports. |
By Andrea Park OPDP director Catherine Gray and deputy director Mark Askine told staffers on Thursday that they were leaving, and their resignations took effect Friday, Politico’s AgencyIQ reports, citing emails shared by sources within the office. |
By Nick Paul Taylor Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. Days after starting to look for partners, the company has moved to lay off 21 of its 26 full-time employees to stretch its limited cash reserves. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
By Conor Hale Medtronic has secured a green light from the FDA to connect its latest automated insulin pump with its newest continuous glucose monitor, following a similar approval for the pairing in Europe early last year. |
By Angus Liu AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly statistically significant” efficacy in a key trial. |
By Nick Paul Taylor Roivant is putting its people at the top of Immunovant—and they have made an immediate mark on the biotech’s pipeline. Having previously planned to target 10 indications, the biotech has narrowed its focus to six settings where it could start delivering potentially registrational data in 2027. |
By Angus Liu In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer, Gilead Sciences’ Trodelvy has notched a much-needed win. |
By Zoey Becker Extra costs and red tape from the U.K.'s split from the European Union have slowed down cancer research in the U.K. and left some patients without lifesaving treatment, a new report obtained by the Guardian reveals. |
By Kevin Dunleavy The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea from a maximum frequency of every 16 weeks to every 24 weeks. The rejection is another blow for Regeneron, which is losing market share to Roche and its eye disease treatment Vabysmo. |
By Andrea Park In a commercial debuting Monday, Kenan Thompson hosts the “Kick Some Acid Cooking Show,” serving up a gourmet meal with over-the-top flair while he discusses how Phathom’s Voquezna helps reduce heartburn associated with his non-erosive GERD. |
By Kevin Dunleavy Sanofi and Regeneron have scored an FDA approval for Dupixent in its seventh indication—chronic spontaneous urticaria (CSU). The nod comes 18 months after the U.S. regulator rejected Dupixent in the same indication. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
|
|---|
|
|
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
